Zali Mahsan, Sadat Larijani Mona, Bavand Anahita, Moradi Ladan, Ashrafian Fatemeh, Ramezani Amitis
Clinical Research Department, Pasteur Institute of Iran, No: 69, Pasteur Ave, Tehran, 1316943551, Iran.
Arch Virol. 2024 Dec 12;170(1):8. doi: 10.1007/s00705-024-06184-3.
The coronavirus disease of 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can alter the expression levels of host microRNAs (miRNAs). Increasing evidence suggests that circulating miRNAs can potentially play an important role in the diagnosis and prognosis of respiratory infectious diseases, especially COVID-19, and might serve as sensitive indicators of disease before the emergence of clinical symptoms. Here, we review the potential of circulatory microRNAs as novel biomarkers for different aspects of COVID-19. Recent studies have suggested that they can be useful not only for COVID-19 prognosis but also for prediction of disease severity and mortality among intensive care unit (ICU) and ward patients. Moreover, extracellular vesicle (EV) miRNAs can be associated with antibody titer after COVID-19 vaccination. This review provides an overview of miRNA-based biomarkers.
2019冠状病毒病（COVID-19）由新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，可改变宿主微小RNA（miRNA）的表达水平。越来越多的证据表明，循环miRNA可能在呼吸道传染病尤其是COVID-19的诊断和预后中发挥重要作用，并且可能在临床症状出现之前作为疾病的敏感指标。在此，我们综述了循环微小RNA作为COVID-19不同方面新型生物标志物的潜力。最近的研究表明，它们不仅可用于COVID-19的预后，还可用于预测重症监护病房（ICU）和病房患者的疾病严重程度和死亡率。此外，细胞外囊泡（EV）miRNA可能与COVID-19疫苗接种后的抗体滴度相关。本综述概述了基于miRNA的生物标志物。
